Moderna signed a 10-year strategic manufacturing agreement with Lonza for mRNA-1273 (Spikevax) and other mRNA medicines. Lonza established production lines in Portsmouth, NH (US) and Visp, Switzerland targeting four manufacturing kits each capable of producing up to 100M doses/year of mRNA-1273. Critical to global COVID-19 vaccine supply chain.
Key facts
AnnouncedMay 01, 2020
ClosedMay 01, 2020
Deal typeCo-Development
Therapeutic areaCOVID-19
IndicationsCOVID-19
Key assetsmRNA-1273 (Spikevax)
MechanismmRNA vaccine encoding SARS-CoV-2 spike protein